GlassScriptPhysician profile
Luis C Gutierrez
NPI 1801882022
$4,824.19
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,881 · 2020: $1,070 · 2021: $825 · 2022: $553 · 2023: $317 · 2024: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,201.92 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $804.56 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $787.03 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Sunovion Pharmaceuticals INC. | $523.94 | 2019-2022 | |
| Alkermes, INC. | $507.84 | 2019-2024 | Lybalvi |
| Neurocrine Biosciences, INC. | $379.66 | 2019-2022 | |
| Allergan, INC. | $308.71 | 2019-2020 | |
| Abbvie INC. | $209.07 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.03 | 2021-2023 | |
| Indivior INC. | $26.56 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $24.14 | 2020 | |
| Vanda Pharmaceuticals INC. | $16.73 | 2023 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.